Abstract
24 depressed inpatients received a standardized treatment by imipramine, 6 among them receiving also levomepromazine. Plasma concentrations of imipramine and DMI were controlled weekly during the study, and standardized assessment of clinical state were made by a psychiatrist who was unaware of biochemical findings.
Interaction between the antidepressant and neuroleptic metabolism is shown by a significant increase of DMI levels, though the clinical effect of the drug association could not be asserted.
The therapeutic effect seems mainly dependant of etiology of depression. Endogeneous depressions improve more than other types. Among endogeneous depressions a significant correlation was found between the degree of clinical improvement after three weeks and DMI level, sum of imipramine + DMI level, but not with concentration of imipramine alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Bibliographie
Alexanderson, B., Evans, D. A., Sjoqvist, F.: Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Brit. med. J. 1969IV, 764–768
Asberg, M., Evans, D. A., Sjoqvist, F.: Genetic control of nortriptyline kinetics in man. A study of relatives of proposity with high plasma concentration. J. Med. Genetics 8, 129–135 (1971)
Asberg, M., Cronholm, B., Sjoqvist, F., Tuck, D.: Relationship between levels and therapeutic effect of nortriptyline. Brit. med. J. 1971III, 331–334
Braithwaite, R. A., Goulding, R., Theano, G., Bailley, J., Coppen, A.: Plasma concentration of amitriptyline and clinical response. Lancet 1972I, 1297–1300
Burrows, G. D., Davies, B., Scoggins, B. A.: Plasma concentrations of nortriptyline and clinical response in depressive illness. Lancet 1972II, 619–623
Dingell, J. V., Sulzer, F., Gillette, J. R.: Species differences in the metabolism of imipramine and desmethylimipramine. J. Pharmacol. exp. Ther. 143, 14–22 (1964)
Gram, L. F., Fredericson-Overo, K.: Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Brit. med. J. 1972I, 463–465
Hammer, W., Sjoqvist, F.: Plasma levels of monomethylated tricyclic antidepressant during treatment with imipramine-like compounds. Life Sci. 6, 1895–1903 (1967)
Haydu, G. G., Quinn, G. P.: Plasma imipramine in the depressions and psychodynamics. Proc. 4th World Congr. Psychiat. Madrid. Abstr. Int. Congr. Serv. No. 150, 1875–1878 (1966)
Moody, J. P., Tait, A. C., Todrick, A.: Plasma levels of imipramine and desmethylimipramine during therapy. Brit. J. Psychiat. 113, 183–193 (1967)
Tillement, J. P.: Pharmacocinetique des antidepresseurs. Thérapie 28, 249–268 (1973)
Walter, C. J. S.: Clinical significance of plasma imipramine levels. Proc. roy. Soc. Med. 64, 282–285 (1971)
Yates, C. M., Todrick, A., Tait, A. C.: Aspects of the clinical chemistry of desmethylimipramine in man. J. Pharm. Pharmacol. 15, 432–439 (1963)
Zeidenberg, P., Perel, J. M., Kauxler, M., Wharton, R. N., Malitz, S.: Clinical and metabolic studies with imipramine in man. Amer. J. Psychiat. 127, 1321–1326 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olivier-Martin, R., Marzin, D., Buschsenschutz, E. et al. Concentrations plasmatiques de l'imipramine et de la desmethylimipramine et effet anti-depresseur au cours d'un traitement controlé. Psychopharmacologia 41, 187–195 (1975). https://doi.org/10.1007/BF00421078
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00421078